PRP for Tennis Elbow (Lateral Epicondylitis)

Does PRP Work for Tennis Elbow?

Yes — PRP has demonstrated superior long-term outcomes compared to corticosteroid injection in multiple randomized controlled trials, with durable pain relief maintained at 12- and 24-month follow-up in patients with chronic lateral epicondylitis. While cortisone provides faster short-term relief, clinical evidence consistently shows that PRP addresses the underlying degenerative pathology in a way that corticosteroids do not, resulting in better outcomes over the 6- to 24-month horizon. At Maryland Orthopedic Specialists in Bethesda and Germantown, Maryland, our board-certified orthopedic physicians offer PRP as a first-line regenerative treatment for patients with chronic tennis elbow that has not resolved with standard conservative care.

Understanding Lateral Epicondylitis

Despite its name, tennis elbow is not primarily a disease of tennis players, nor is it technically an inflammatory condition — making the term "epicondylitis" something of a misnomer. The correct pathological descriptor is tendinosis: a degenerative process characterized by collagen fiber disorganization, mucoid degeneration, and fibroblast proliferation within the tendon tissue, occurring in the near-absence of the inflammatory cells one would expect in true tendinitis. This distinction matters because it explains why anti-inflammatory treatments such as cortisone provide only temporary relief — they suppress an inflammatory response that is not the primary driver of the condition.

Lateral epicondylitis affects approximately 1–3% of the general population and accounts for more than 200,000 new clinical presentations per year in the United States. It most commonly affects adults between 35 and 54 years of age — particularly those who perform repetitive forearm rotation and wrist extension activities, whether in occupational settings (assembly line workers, dental hygienists, carpenters) or recreational ones (racquet sport athletes). The condition produces characteristic pain at the lateral epicondyle of the humerus, reproduced with grip strength, resisted wrist extension, and everyday tasks such as lifting a coffee cup or opening a jar. The extensor carpi radialis brevis (ECRB) tendon origin is the most commonly affected structure. Healing is notoriously slow: the ECRB tendon origin is relatively hypovascular, meaning it receives poor blood supply and therefore limited access to the growth factors required for tissue repair — a biological deficit that PRP is specifically designed to address.

Why PRP Works for Tendinopathy

The rationale for PRP in lateral epicondylitis is rooted in the pathophysiology of tendinosis. Because the ECRB tendon origin is poorly vascularized, the natural healing response — which depends on platelet activation and growth factor delivery at the site of injury — is blunted. PRP directly corrects this deficiency by delivering a supraphysiological concentration of platelets, and therefore a supraphysiological concentration of their associated growth factors, precisely to the site of degeneration.

The most therapeutically relevant growth factors in this context include platelet-derived growth factor (PDGF), which drives tenocyte proliferation, and transforming growth factor-beta (TGF-β), which stimulates collagen type I synthesis — the structural protein fundamental to tendon integrity. Vascular endothelial growth factor (VEGF) promotes angiogenesis, establishing new capillary networks that improve the long-term vascular supply to the tendon. Taken together, these factors shift the tendon from a failed healing state toward an active repair state.

This stands in direct contrast to corticosteroid injection. Cortisone reduces pain and swelling in the short term by suppressing local inflammation — an effect that is rapid but, in the context of tendinosis, somewhat disconnected from the primary pathology. More significantly, repeated corticosteroid injections have been associated with collagen fiber disruption, reduced tenocyte viability, and an increased risk of tendon rupture with serial use. PRP, by stimulating endogenous repair mechanisms, targets the degenerative pathology directly and does not carry these catabolic risks.

Clinical Evidence: Literature Review

The evidence base for PRP in lateral epicondylitis includes several well-designed randomized controlled trials and systematic reviews. The following studies represent the core literature informing treatment decisions at Maryland Orthopedic Specialists.

Mishra AK, et al. — American Journal of Sports Medicine, 2014

Citation: Mishra AK, Skrepnik NV, Edwards SG, et al. Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multicenter, randomized controlled trial. American Journal of Sports Medicine. 2014;42(2):463–471. DOI: 10.1177/0363546513494359

This is one of the landmark US trials of PRP for tennis elbow. The study enrolled 230 patients with chronic lateral epicondylitis (symptoms for at least 3 months, failure of conservative treatment) at multiple centers and randomized them to ultrasound-guided PRP injection versus whole blood injection — both active treatment groups, with the whole blood arm serving as an active control. The study was double-blind; neither patients nor the physicians performing outcome assessments knew which treatment had been administered. Using the Patient-Rated Tennis Elbow Evaluation (PRTEE) scale as the primary outcome at 24 weeks, PRP produced a 71.5% rate of improvement, compared to 56.1% in the whole blood group — a statistically significant and clinically meaningful difference. PRP patients also demonstrated superior rates of treatment success based on predetermined threshold criteria. This multicenter design, large sample size, and rigorous blinding make this one of the strongest US trials supporting PRP for lateral epicondylitis.

Gosens T, et al. — American Journal of Sports Medicine, 2011

Citation: Gosens T, Peerbooms JC, van Laar W, den Oudsten BL. Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind randomized controlled trial with 2-year follow-up. American Journal of Sports Medicine. 2011;39(6):1200–1208. DOI: 10.1177/0363546510397173

This two-year follow-up RCT enrolled 100 patients with chronic lateral epicondylitis and randomized them to either a single PRP injection or a single corticosteroid injection. Outcomes were measured using the VAS pain score, grip strength, and the DASH questionnaire at multiple time points through 24 months. The results reveal a striking temporal pattern: at 4 weeks, corticosteroid was significantly superior to PRP — consistent with its established anti-inflammatory effect. However, at 8 weeks, PRP had surpassed corticosteroid performance, and it maintained statistically significant superiority at every subsequent time point through the 2-year mark. By 2 years, the cortisone group had not only lost its early advantage but had deteriorated to near-baseline levels, while the PRP group maintained substantial, durable improvement. This trial is clinically significant because it demonstrates both the relative advantage of each treatment and the fundamental difference in their mechanisms: cortisone suppresses; PRP repairs.

Krogh TP, et al. — American Journal of Sports Medicine, 2013

Citation: Krogh TP, Bartels EM, Ellingsen T, et al. Comparative effectiveness of injection therapies in lateral epicondylitis: a systematic review and network meta-analysis. American Journal of Sports Medicine. 2013;41(6):1435–1446. DOI: 10.1177/0363546512473258

This network meta-analysis aggregated data from 17 randomized controlled trials with a combined population of 1,381 patients, comparing multiple injection therapies for lateral epicondylitis: PRP, autologous blood, corticosteroid, botulinum toxin, and saline. Using a Bayesian network approach to simultaneously compare all treatment options, the analysis found that PRP ranked highest for pain reduction at the 6-month timepoint among all injection therapies evaluated. Corticosteroid performed best at 4–8 weeks but fell behind all active biological therapies at 6 months. At the 6-month mark, both PRP and autologous blood were statistically superior to saline and cortisone for pain outcomes. The authors concluded that the existing evidence supports PRP as the preferred injection therapy for lateral epicondylitis at mid- and long-term follow-up — with the important caveat that short-term pain management in the first 4–8 weeks may still favor cortisone when immediate relief is the priority.

Arirachakaran A, et al. — Journal of Hand Surgery (European Volume), 2016

Citation: Arirachakaran A, Sukthuayat A, Sisayanarane T, Laoratanavoraphong S, Kanchanatawan W, Kongtharvonskul J. Platelet-rich plasma versus autologous blood versus steroid injection in lateral epicondylitis: systematic review and network meta-analysis. Journal of Hand Surgery (European Volume). 2016;41(9):914–924.

This systematic review and network meta-analysis extended prior evidence by confirming PRP as the preferred long-term injection therapy for lateral epicondylitis when compared against autologous blood, corticosteroid, and saline controls. Of particular clinical relevance, the analysis documented a significant rebound phenomenon associated with corticosteroid injection: by 3 months post-injection, patients in the cortisone arms showed deterioration toward — and in many cases beyond — baseline pain levels, consistent with the natural rebound of an untreated degenerative process once the anti-inflammatory effect dissipates. In contrast, the PRP group maintained progressive improvement through the 6-month and 12-month time points. The authors reaffirmed that PRP's mechanism — stimulating repair rather than suppressing inflammation — produces a fundamentally different and more durable biological outcome than cortisone, and that this should guide treatment selection in patients presenting with chronic lateral epicondylitis of more than 3 months' duration.

Who Is a Good Candidate for PRP?

• Chronic lateral epicondylitis (symptoms ≥ 3 months) — Acute tennis elbow (< 6 weeks; try rest and PT first)
• Failed eccentric exercise, PT, bracing, and/or NSAIDs — Active infection at the injection site
• Experienced worsening or rebound after cortisone — Platelet dysfunction or thrombocytopenia
• Seeking to avoid surgery (lateral epicondyle release) — Use of anticoagulants (evaluated individually)
• Athletes or workers needing durable, long-term relief — Patients unable to avoid NSAIDs post-injection
• Concerns about tendon weakening from repeated steroids — Unrealistic expectations for immediate pain relief

Treatment Protocol at Maryland Orthopedic Specialists

Evaluation and Diagnosis All patients undergo a thorough clinical evaluation to confirm the diagnosis of lateral epicondylitis and rule out alternative or concurrent pathology (radial tunnel syndrome, cervical radiculopathy, posterior interosseous nerve entrapment). Diagnostic musculoskeletal ultrasound may be performed in-office to assess ECRB tendon integrity, identify areas of tendinosis, confirm degenerative changes, and guide injection placement. MRI may be ordered when clinical findings are unclear or when a partial tear is suspected.

The PRP Procedure

1. A blood sample (30–60 mL) is drawn from the patient's peripheral vein.
2. The blood is centrifuged to separate and concentrate the platelet-rich plasma layer.
3. The concentrated PRP is injected under real-time ultrasound guidance directly into the area of tendinosis at the ECRB origin on the lateral epicondyle.
4. The use of ultrasound guidance ensures accurate delivery to the degenerative tissue zone, which improves outcomes compared to landmark-guided injection.

Post-Injection Protocol

• Avoid NSAIDs (ibuprofen, naproxen, aspirin) for at least 2 weeks post-injection, as they inhibit platelet activation and may blunt the treatment effect.
• Limit heavy gripping, lifting, and racquet sports for 48–72 hours.
• Begin or resume a supervised eccentric strengthening program for the wrist extensors at 2–4 weeks post-injection, as eccentric loading is synergistic with PRP in tendon remodeling.
• Follow-up appointment at 4–6 weeks to assess response.

Typical Injection Series

• For most patients with chronic lateral epicondylitis: 1 injection, with re-evaluation at 6–8 weeks.
• If partial response: a second injection may be administered at 6–8 weeks.
• Most published trials used a single PRP injection; evidence for a second injection in partial responders is supported by clinical practice but less extensively by controlled trials.

Timeline to Results

• Initial improvement: 4–6 weeks (PRP does not produce the rapid 1–2 week relief of cortisone).
• Meaningful functional improvement: 6–12 weeks.
• Peak benefit: 3–6 months.
• Durability: 12–24 months; sustained improvement documented at 2 years in published trials.

Frequently Asked Questions